Caregiver

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, NSCLC, Fatigue, Epithelioid hemangioendothelioma, TEAD, Diarrhea, Physician, Hippopotamus, Weight gain, Meningioma, Liver, Quarter, Wind, Additive effect, Nausea, NF2, Quality of life, Growth, Disease, Caregiver, Clinical trial, Neoplasm, TEAD1, Biology, DLT, Cancer, Partnership, Collaboration, Mesothelioma, Liver failure, Nephrotoxicity, Blood, Pain, Patient, VGLL4, TAZ, EHE, Therapeutic index, Proteinuria, Pharmaceutical industry, Vaccine, Cryptocurrency, Pionýr

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Aveanna Healthcare Holdings Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Sale, Government, Public expenditure, EBITDA, HHH, GAAP, Acquisition, Health, Maintenance, Software, Nature, Growth, Caregiver, COVID, COVID-19, Income tax, Interim, Rising Medical Solutions, Depreciation, PDS, Patient, Video game, Life insurance, Bookkeeping, Pharmaceutical industry, Cryptocurrency, Bank, Security (finance), Risk management, Insurance, Adjustment, Q3

These strong results further affirm the Aveanna strategy to adapt and transform our business as we execute on our 2023 key initiatives.

Key Points: 
  • These strong results further affirm the Aveanna strategy to adapt and transform our business as we execute on our 2023 key initiatives.
  • I am proud of our Aveanna teammates' efforts and the solid results they produced for the third quarter.
  • Net loss was $102.4 million for the third quarter of 2023, as compared to net income of $24.3 million for the third quarter of 2022, primarily attributable to a $105.1 million non-cash goodwill impairment charge recorded in the third quarter of 2023.
  • Aveanna will host a conference call on Thursday, November 9, 2023, at 10:00 a.m. Eastern Time to discuss our third quarter 2023 results.

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis

Retrieved on: 
Thursday, November 9, 2023
Lazarus, Pulmonary fibrosis, Lake, HRCT, Idiopathic pulmonary fibrosis, IPF, FVC, Summit, OLE, Disease, Caregiver, ATLAS, ILD, Vital capacity, Safety, Patient, PFF, FCCP, Outline, Pharmaceutical industry

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced the presentation of preclinical data that supported the completed Phase 1a trial of AP02 (inhaled nintedanib) as well as clinical data for AP01 (inhaled pirfenidone) at the 2023 Pulmonary Fibrosis Foundation (PFF) Summit at the JW Marriott Grande Lakes in Orlando, FL.

Key Points: 
  • “We are excited to engage with the pulmonary fibrosis community at the PFF Summit, including people living with the disease, their caregivers and the expert providers that support them, and to share data for our inhaled treatment candidates AP01 and AP02,” said Howard M. Lazarus, M.D.
  • These data demonstrated that inhaled nintedanib was well-tolerated, was indicative of efficient inhaled alveolar deposition, and delivered oral-superior lung levels with reduced systemic exposure.
  • Avalyn will also review the results from the Phase 1b trial of AP01 (ATLAS) in participants with idiopathic pulmonary fibrosis (IPF).
  • The OLE enrolled ATLAS participants and AP01-naïve pulmonary fibrosis participants, and the data showed a durable and consistent response to AP01, including fewer reported adverse events compared to historical reports of oral pirfenidone.

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Research, Sale, IND, AAV, Rare disease, Acquisition, Cardiology, Solid, Caregiver, Duchenne, Choroideremia, CMO, Investment, Patient, CPVT, Hypertrophic cardiomyopathy, Pharmaceutical industry, Cryptocurrency, Pfizer

CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • “We are pleased with the continued advancement of our diversified pipeline of neuromuscular and cardiac gene therapies; including an IND submission in this quarter for SGT-003 for patients with Duchenne,” said Bo Cumbo, President and CEO of Solid Biosciences.
  • “We continue to expand our pipeline and last quarter licensed in a gene transfer program to treat catecholaminergic polymorphic ventricular tachycardia (CPVT).
  • Net loss for the third quarter of 2023 was $21.0 million, compared to $20.4 million for the third quarter of 2022.
  • Solid had $142.9 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2023, compared to $213.7 million as of December 31, 2022.

Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians

Retrieved on: 
Thursday, November 9, 2023
Managed Care, General Health, Professional Services, Training, Consumer, Mental Health, Education, Health Insurance, Cardiology, Insurance, Seniors, Health, Diabetes, Knowledge, Humana, Alzheimer's disease, Dementia, NYSE, Family, Physician, Brain, Quality of life, Caregiver, Partnership, Medicaid, Patient, Diagnosis, Pharmaceutical industry, Nursing

Dementia is often used as a general term for cognitive decline, but there are many and varied forms of the condition.

Key Points: 
  • Dementia is often used as a general term for cognitive decline, but there are many and varied forms of the condition.
  • We knew that with the right partnership, we could be part of the solution and bust this barrier to better wellbeing,” said Natalia Aresu, President, Humana Healthy Horizons Florida.
  • Train the Trainer: Humana Healthy Horizons LTC Care Managers from each Medicaid region will receive training from the Alzheimer’s Association that will provide them the opportunity to be Alzheimer’s trainers.
  • Since launching its Humana Healthy Horizons brand in 2020, the company (including today’s announcement), through Humana Healthy Horizons and its philanthropic arm, the Humana Foundation, has invested nearly $8 million in Florida nonprofit organizations – in support of some 200 nonprofits.

Veterans Health Administration Partners with CoSo Cloud to Enhance Employee Training Experience

Retrieved on: 
Thursday, November 9, 2023
Health Technology, Security, Data Management, Technology, Human Resources, Education, Training, Apps, Applications, Professional Services, General Health, Defense, Veterans, Software, Internet, Health, Cloud, WSNC, Workforce, Science and technology in Asia, VHA, Caregiver, Partnership, Visn, NASA Integrated Services Network, ALM, Coso, Risk management

CoSo Cloud LLC (CoSo), a Class Technologies company and leading provider of secure, private cloud-managed services and custom applications for high-consequence eLearning and virtual training, announced a partnership with the Western States Network Consortium (WSNC).

Key Points: 
  • CoSo Cloud LLC (CoSo), a Class Technologies company and leading provider of secure, private cloud-managed services and custom applications for high-consequence eLearning and virtual training, announced a partnership with the Western States Network Consortium (WSNC).
  • The partnership provides access to self-paced training opportunities for supervisors, human resources, and administrative staff.
  • WSNC encompasses five Veterans Integrated Service Networks (VISN) that provide healthcare services to more than 2.7 million veterans and their caregivers in 18 U.S. states and territories.
  • For more information about CoSo Cloud, please visit www.cosocloud.com .

Visory Health Names Highly Decorated Army Colonel to Serve as Chief Clinical Officer

Retrieved on: 
Thursday, November 9, 2023
Health, Defense, Other Health, Health Insurance, General Health, Veterans, Risk, Operation Provide Promise, RAND, CSH, United States Army Human Resources Command, Veterans Health Administration, United Nations Protection Force, Medical-surgical nursing, AAS, Principal investigator, Courage, Order of Military Medical Merit, United Nations, Combat support hospital, Operation, Empowerment, 67th Combat Support Hospital (United States), Research, University, Capital region, Caregiver, Prescription, ID, Visori, War, Defense Health Agency, Woman, Army, Civica Rx, Harvard University, Consultant, Health insurance, Nursing, Veteran

Visory Health , a simple, patient-first platform that provides lower prices on prescriptions, announces the appointment of highly decorated Army Colonel Dr. Cheryl Creamer as the company’s Chief Clinical Officer.

Key Points: 
  • Visory Health , a simple, patient-first platform that provides lower prices on prescriptions, announces the appointment of highly decorated Army Colonel Dr. Cheryl Creamer as the company’s Chief Clinical Officer.
  • Veterans often face significant challenges when it comes to accessing healthcare, particularly in terms of mental health support and prescription medications.
  • According to RAND research , only about half of all veterans who need mental health care ever receive it due to a series of roadblocks.
  • Dr. Creamer brings unmatched expertise, leadership and compassion to Visory Health, positioned as a liaison between Veterans and affordable medications.

Black Rifle Coffee Company and UFC® Join the Fight Against Service-Related Illness with HunterSeven Foundation

Retrieved on: 
Thursday, November 9, 2023
Retail, Other Professional Services, Other Health, Radiology, Martial Arts, Oncology, General Health, Professional Services, Philanthropy, Defense, Sports, Foundation, Veterans, Other Philanthropy, Food, Beverage, Health, Insurance, Education, Coffee, NYSE, Life, Veteran, BRCC, UFC, Research, Friends, Madison Square Garden, Caregiver, TKO, The Global War on Terrorism Memorial Foundation, Black Rifle Coffee Company, Woman, Cancer, Hospital

“As I think back on my time in uniform, I remember those lost not from combat, but from cancer,” said Chelsey Simoni, HunterSeven Foundation Co-Founder and Executive Director.

Key Points: 
  • “As I think back on my time in uniform, I remember those lost not from combat, but from cancer,” said Chelsey Simoni, HunterSeven Foundation Co-Founder and Executive Director.
  • “More than a half million of our fellow warfighters have been diagnosed with cancer during the Global War on Terror.
  • The groundbreaking work that the HunterSeven Foundation is doing is personal to me and to every person who has ever worn this country’s uniform.
  • To learn more about HunterSeven Foundation and to donate, visit: https://hunterseven.org/ufc295 .

Honoring Our Nations Veterans: New Veterans Resources Guide Unveiled to Unlock Vital Benefits to Support Our Heroes at Life's End.

Retrieved on: 
Thursday, November 9, 2023
U.S. Department of Veterans Affairs, Office of Inspector General, Ageing, National Partnership, Health care, NPHI, SBP, Hospice, Caregiver, Defense Finance and Accounting Service, United States Department of Veterans Affairs, Palliative care, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Veterans Day, Pay, Tuskegee Veterans Administration Medical Center, Hospital, Management, Veteran

These resources encompass not only those provided by the Veterans Administration but also vital state and local services.

Key Points: 
  • These resources encompass not only those provided by the Veterans Administration but also vital state and local services.
  • In addition, the guide offers insights into military pay, retirement pay, and survivor benefits, all administered through the Defense Finance and Accounting Services.
  • "The 'Serving Those Who Served Us' Veterans Resources Guide is a testament to NPHI's dedication to enhancing the lives of our Veterans," said Tom Koutsoumpas, NPHI CEO.
  • While the U.S. Department of Veterans Affairs (VA) provides a range of benefits for Veterans, many of these services are underutilized or difficult to access.

Betterleave Raises Funding to Transform How Organizations Support Their Members Through Grief and Loss

Retrieved on: 
Thursday, November 9, 2023
Grief, Abbott, Insurance, AARP, Ageing, Humana, Prevalence, Face, Workplace, Organization, Cigna, Butter, Hospice, Caregiver, Curriculum, Partnership, Interfor, Aetna, Traction, Patient, Diagnosis, AngelList, Communication, Animal, COVID-19, Mental health, Evansville Vanderburgh School Corporation, Nursing, United, Bread

AUSTIN, Texas, Nov. 9, 2023 /PRNewswire/ -- Betterleave, a pioneering platform that partners with organizations to improve access, experience, and outcomes, while lowering the total cost of bereavement care, today announced it has raised $2.4 million in funding. The round was led by Chingona Ventures, with participation from Bread and Butter Ventures, Vitalize VC, Wisdom Ventures Fund, Coyote Ventures and AARP. Betterleave brings a differentiated, integrated approach to grief and mental health, by offering a comprehensive digital and clinical care solution that addresses the complex challenges individuals face when preparing for and navigating bereavement.

Key Points: 
  • Bereavement is a growing category of care designed to help organizations connect with and support members during the grieving process.
  • Despite the prevalence of grief, there has been a critical gap in support and resources to navigate the professional, financial, and emotional challenges of loss.
  • It covers the entire bereavement spectrum, from pre-need to immediate need, loss navigation, and continuous grief support.
  • The platform specializes in various types of grief, including but not limited to the loss of a loved one, pregnancy loss, pet loss, anticipatory loss and relationship loss.